ARK provides an automated insurance compliance solution that utilizes AI and large language models to evaluate Certificates of Insurance and Insurance Policies in as little as 10 seconds. This technology enables brokers, risk managers, and policyholders to quickly identify problematic exclusions and reduce administrative costs associated with compliance management.

The startup develops gene therapy drugs that utilize proprietary protein therapeutics to target chronic eye diseases. By improving viral vector production, the company provides patients with effective and long-lasting treatments that are both safe and affordable.

C4 Therapeutics develops targeted protein degradation therapies that specifically eliminate disease-causing proteins, utilizing a proprietary approach to induce selective protein removal. This technology aims to address the underlying causes of diseases, potentially transforming treatment outcomes for patients with conditions linked to dysfunctional proteins.

Cullgen develops targeted protein degraders using proprietary E3 ligands to address diseases that currently lack effective therapies, such as certain cancers. Their technology enables the degradation of previously undruggable proteins, offering a new approach to drug discovery and development.

Dermaliq Therapeutics utilizes its proprietary hyliQ® technology to enhance the targeted delivery of active ingredients into skin tissues and hair follicles, significantly improving bioavailability without the need for irritating excipients. This approach addresses the challenges of treating dermatological conditions such as alopecia and psoriasis by providing effective topical therapies with reduced systemic side effects.

Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, which are implicated in the dysregulation of complex diseases. By integrating AI with advanced experimental technologies, the company aims to create therapies for conditions previously considered undruggable.

Eaglenos develops point-of-care testing (POCT) devices and health management systems that utilize electrochemical detection and advanced sensing materials to provide accurate health diagnostics. The company addresses the need for personalized health management solutions in home healthcare settings, enhancing patient monitoring and treatment outcomes.

The startup develops a mid-infrared fiber laser system designed for original equipment manufacturers in the medical device sector, providing alternatives for aesthetic, surgical, and marking applications. Their platform enables clients to enhance operational profitability in global markets by offering tailored solutions for diverse medical device needs.

The startup develops an ultrasensitive nanoarray analyzer that utilizes flow cytometry to digitally detect single proteins or nucleic acids through biomarker-linked nanoparticle complexes. This technology enables researchers to achieve single-molecule resolution in biomarker quantification, enhancing laboratory tests for disease prevention and promoting wellness.

This company provides a platform for investing in US and global markets through a mobile application. It leverages Artificial Intelligence and Machine Learning to optimize investment profitability across various products like managed portfolios, thematic portfolios, and individual stocks/ETFs. Investors gain access to internationally regulated investment products with dollarized accounts for simplified global capital deployment.

LumiThera develops the Valeda Light Delivery System, an FDA-authorized medical device that utilizes LED and laser technology to treat dry age-related macular degeneration (AMD). This system aims to improve visual acuity in patients with specific retinal conditions, addressing the leading cause of blindness in adults over 65.

MineOS is a data privacy and governance platform that utilizes AI-driven data mapping and classification techniques to automate compliance with privacy regulations. It addresses the challenges of managing sensitive information and data subject requests by providing centralized workflows and real-time visibility across diverse data sources.

Myrobalan Therapeutics develops first-in-class and best-in-class oral small molecule therapies targeting neuroinflammation and demyelination in CNS diseases. The company focuses on identifying potent, selective, and brain-penetrant compounds for conditions like multiple sclerosis and Alzheimer's disease. They utilize biomarker-guided precision neurology to deliver innovative treatments to appropriate patient populations.

NeuralGalaxy is focused on developing neurobiological therapies to treat brain disorders such as Alzheimer's and Parkinson's disease. The company utilizes advanced neuroimaging and biomarker analysis to identify and target specific neural pathways affected by these conditions, improving patient outcomes through precision medicine.

This company develops first-in-class and best-in-class therapeutic candidates for hard-to-treat cancers and Alzheimer’s disease. They leverage innate and adaptive immune checkpoints, including CTLA-4, CD24, and Siglec, to enhance immune response against cancer cells. Their pipeline utilizes diverse modalities such as monoclonal antibodies, bispecific antibodies, ADCs, and CAR T-cell therapies to create safer and more durable treatments.

ProNovo Therapeutics develops novel, precision therapeutics targeting unmet medical needs in neuropsychiatric disorders like Major Depressive Disorder and Schizophrenia. The company integrates genetic susceptibility and prognostic biomarkers into its de-risked medicine strategy to create high-impact treatments. Its pipeline includes first-in-class and best-in-class opportunities for depression and schizophrenia, respectively.

Rapafusyn Pharmaceuticals develops RapaGlues™, a novel class of non-degrading molecular glues that facilitate protein-protein interactions by bringing the FKBP12 chaperone protein in proximity to previously undruggable intracellular targets. This technology addresses the lack of effective therapies for conditions like acute kidney injury and various cancers by enabling selective inhibition of critical protein functions.

Reneo is a pharmaceutical company focused on developing therapies for rare genetic mitochondrial diseases caused by mitochondrial dysfunction in adenosine triphosphate production. Their approach targets the underlying biochemical pathways to improve energy metabolism in affected patients, addressing significant unmet medical needs in this niche area.

Smartlens, Inc. develops miLens, a non-invasive device that continuously monitors intraocular pressure (IOP) to provide real-time data for glaucoma management. Their THERmic technology delivers personalized microdose treatments based on the patient's diurnal IOP, addressing the challenge of inadequate monitoring and treatment of glaucoma patients.

Subtle Medical develops AI-powered software solutions, SubtleMR™ and SubtlePET™, that enhance image quality and reduce acquisition time for MRI and PET scans. This technology addresses the challenges of long wait times and suboptimal imaging, enabling healthcare providers to improve patient throughput and maintain diagnostic confidence.

Twist Bioscience offers a semiconductor-based DNA synthesis platform for high-throughput, cost-effective production of custom DNA. Their technology enables rapid generation of genes, oligo pools, and variant libraries, accelerating research in synthetic biology, drug discovery, and diagnostics.